155 related articles for article (PubMed ID: 25161377)
21. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Koiwa F; Sato Y
Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
[TBL] [Abstract][Full Text] [Related]
22. Phosphorus Counting Table for the control of serum phosphorus levels without phosphate binders in hemodialysis patients.
Bertonsello-Catto VR; Lucca LJ; da Costa JAC
Clin Nutr ESPEN; 2019 Aug; 32():153-157. PubMed ID: 31221281
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
[TBL] [Abstract][Full Text] [Related]
24. Use of calcium carbonate as a phosphate binder in dialysis patients.
Hercz G; Kraut JA; Andress DA; Howard N; Roberts C; Shinaberger JH; Sherrard DJ; Coburn JW
Miner Electrolyte Metab; 1986; 12(5-6):314-9. PubMed ID: 3807829
[TBL] [Abstract][Full Text] [Related]
25. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
[TBL] [Abstract][Full Text] [Related]
26. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
27. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618
[TBL] [Abstract][Full Text] [Related]
28. Reasons for phosphate binder discontinuation vary by binder type.
Wang S; Anum EA; Ramakrishnan K; Alfieri T; Braunhofer P; Newsome B
J Ren Nutr; 2014 Mar; 24(2):105-9. PubMed ID: 24462496
[TBL] [Abstract][Full Text] [Related]
29. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
30. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
31. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.
Lopes AA; Tong L; Thumma J; Li Y; Fuller DS; Morgenstern H; Bommer J; Kerr PG; Tentori F; Akiba T; Gillespie BW; Robinson BM; Port FK; Pisoni RL
Am J Kidney Dis; 2012 Jul; 60(1):90-101. PubMed ID: 22385781
[TBL] [Abstract][Full Text] [Related]
32. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
33. Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
Locatelli F; Dimkovic N; Spasovski G
Expert Rev Endocrinol Metab; 2015 Mar; 10(2):131-142. PubMed ID: 30293511
[TBL] [Abstract][Full Text] [Related]
34. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
35. MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.
Evsanaa B; Liu I; Aliazardeh B; Mahdavi S; Bajwa G; Gula J; Tam M; Sze E; Roscoe JM; Tam PY; Sikaneta T
Perit Dial Int; 2015; 35(1):31-4. PubMed ID: 24584605
[TBL] [Abstract][Full Text] [Related]
36. The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia.
Daoud K; Badran H; Anwar N; Nguyen T
Nephrol Nurs J; 2023; 50(2):140-144. PubMed ID: 37074939
[TBL] [Abstract][Full Text] [Related]
37. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
38. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.
Nadin C
Core Evid; 2005; 1(1):43-63. PubMed ID: 22496676
[TBL] [Abstract][Full Text] [Related]
39. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
Assimon MM; Mousa S; Shaker O; Pai AB
Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816
[TBL] [Abstract][Full Text] [Related]
40. Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease.
Wu PH; Liu PY; Chiu YW; Hung WC; Lin YT; Lin TY; Hung SC; Delicano RA; Kuo MC; Wu CY
Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33419265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
